190 related articles for article (PubMed ID: 31157737)
21. Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.
Daud A; Gill J; Kamra S; Chen L; Ahuja A
J Hematol Oncol; 2017 Jan; 10(1):3. PubMed ID: 28052762
[TBL] [Abstract][Full Text] [Related]
22. Cobimetinib.
Signorelli J; Shah Gandhi A
Ann Pharmacother; 2017 Feb; 51(2):146-153. PubMed ID: 27701080
[TBL] [Abstract][Full Text] [Related]
23. Effect of early adverse events on response and survival outcomes of advanced melanoma patients treated with vemurafenib or vemurafenib plus cobimetinib: A pooled analysis of clinical trial data.
Hopkins AM; Van Dyk M; Rowland A; Sorich MJ
Pigment Cell Melanoma Res; 2019 Jul; 32(4):576-583. PubMed ID: 30758912
[TBL] [Abstract][Full Text] [Related]
24. Undifferentiated Sarcoma as Intermediate Step in Rhabdomyosarcomatous Transformation of a Metastatic Malignant Melanoma Resistant to Anti-BRAF Therapy: A Phenomenon Associated With Significant Diagnostic and Therapeutic Pitfalls.
Tran TAN
Int J Surg Pathol; 2019 Sep; 27(6):669-677. PubMed ID: 30942107
[TBL] [Abstract][Full Text] [Related]
25. Treating malignant melanoma when a rare BRAF V600M mutation is present: case report and literature review.
Popescu A; Haidar A; Anghel RM
Rom J Intern Med; 2018 Jun; 56(2):122-126. PubMed ID: 29168975
[TBL] [Abstract][Full Text] [Related]
26. The role of triple therapy and therapy sequence in treatment of BRAF-mutant metastatic melanoma. Response to overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 study.
Dummer R; Welti M; Ramelyte E
J Transl Med; 2023 Aug; 21(1):529. PubMed ID: 37543586
[TBL] [Abstract][Full Text] [Related]
27. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.
Mey UJM; Renner C; von Moos R
Hematol Oncol; 2017 Dec; 35(4):890-893. PubMed ID: 27641727
[TBL] [Abstract][Full Text] [Related]
28. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
[TBL] [Abstract][Full Text] [Related]
29. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
Ascierto PA; Ribas A; Larkin J; McArthur GA; Lewis KD; Hauschild A; Flaherty KT; McKenna E; Zhu Q; Mun Y; Dréno B
J Transl Med; 2020 Aug; 18(1):294. PubMed ID: 32746839
[TBL] [Abstract][Full Text] [Related]
30. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF
Lewis K; Hauschild A; Larkin J; Ribas A; Flaherty KT; McArthur GA; Dréno B; McKenna E; Zhu Q; Mun Y; Ascierto PA
Eur J Cancer; 2019 Jul; 116():45-55. PubMed ID: 31173962
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison.
Atkins MB; Tarhini A; Rael M; Gupte-Singh K; O'Brien E; Ritchings C; Rao S; McDermott DF
Immunotherapy; 2019 May; 11(7):617-629. PubMed ID: 30852924
[TBL] [Abstract][Full Text] [Related]
32. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793
[TBL] [Abstract][Full Text] [Related]
33. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
34. Cobimetinib plus atezolizumab in BRAF
Gogas H; Dréno B; Larkin J; Demidov L; Stroyakovskiy D; Eroglu Z; Francesco Ferrucci P; Pigozzo J; Rutkowski P; Mackiewicz J; Rooney I; Voulgari A; Troutman S; Pitcher B; Guo Y; Yan Y; Castro M; Mulla S; Flaherty K; Arance A
Ann Oncol; 2021 Mar; 32(3):384-394. PubMed ID: 33309774
[TBL] [Abstract][Full Text] [Related]
35. Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.
Eagles JR; Jimeno A
Drugs Today (Barc); 2016 Nov; 52(11):593-605. PubMed ID: 28112278
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
Hopkins AM; Rathod AD; Rowland A; Kichenadasse G; Sorich MJ
BMC Cancer; 2020 Feb; 20(1):157. PubMed ID: 32103736
[TBL] [Abstract][Full Text] [Related]
37. Cobimetinib and vemurafenib for the treatment of melanoma.
Boespflug A; Thomas L
Expert Opin Pharmacother; 2016; 17(7):1005-11. PubMed ID: 26999478
[TBL] [Abstract][Full Text] [Related]
38. First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor.
Bickel A; Diem S; Flatz L; Stinn B; Siano M
J Cancer Res Ther; 2021; 17(1):276-278. PubMed ID: 33723170
[TBL] [Abstract][Full Text] [Related]
39. Characterization and Outcomes of Disease Progression in 52 Patients Treated with BRAF-V600 + MEK Inhibitors for Advanced Melanoma.
Lucas P; Boulinguez S; Sibaud V; Mourey L; Lamant L; Paul C; Meyer N
Dermatology; 2018; 234(3-4):92-98. PubMed ID: 30110681
[TBL] [Abstract][Full Text] [Related]
40. The new paradigm of systemic therapies for metastatic melanoma.
Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]